PMGC Holdings Inc. — Filing identity and reporting period
Important identity discrepancy: The supplied filing is Elevai Labs Inc.’s Form 10-K, not a PMGC Holdings Inc. filing. It reports the fiscal year ended December 31, 2023, with FY2022 comparisons; it is an annual report, not a standalone fourth-quarter report.
Business context
Elevai develops and sells topical physician-dispensed skincare products featuring stem-cell-derived exosomes. Its main products are Empower and Enfinity; the company also sells white-label products. The filing states the products are cosmetics, not FDA-approved drugs or regenerative medicine, and that clinical validation of aesthetic-performance claims remains incomplete.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $1.713 million | $766,277 |
| Gross profit / margin | $1.135 million / 66% | $447,309 / 58% |
| Operating expenses | $4.901 million | $2.238 million |
| Loss from operations | $3.766 million | $1.791 million |
| Net loss | $4.302 million | $1.800 million |
| Basic and diluted loss per share | $0.400 | $0.189 |
| Cash used in operating activities | $4.557 million | $1.586 million |
At December 31, 2023, cash was $3.327 million, current assets $4.919 million, current liabilities $1.297 million, and working capital $3.622 million. Total liabilities were $1.363 million, including $369,158 of derivative liabilities and $210,489 of operating lease liabilities. The filing reports no notes payable outstanding at year-end. Cash provided by financing activities was $6.739 million, including $6.0 million of IPO proceeds and $1.464 million from a private placement. The company reported an accumulated deficit of $7.024 million.
Material changes versus FY2022
- Revenue more than doubled, increasing $946,318 (about 123%). Enfinity revenue rose to $857,796 and Empower to $619,999; white-label distributor revenue fell to $234,800 from $344,018.
- Gross margin improved by 8 percentage points, attributed to a higher mix of branded products, operational efficiencies, lower relative inventory write-downs, and supplier pricing.
- Net loss widened by $2.501 million. Operating expenses rose $2.662 million, notably office and administration, marketing, professional fees, and R&D. FY2023 also included a $450,079 listing expense and a $71,266 loss from changes in derivative fair value.
- Operating cash outflow increased by $2.971 million. Cash increased year over year primarily because of equity financing, including the November 2023 IPO.
Outlook, commentary, risks, and unusual items
- Management plans to grow sales, conduct clinical validation studies, develop products, expand international distribution, and consider strategic acquisitions. It anticipates that doubling production capacity in 2025 could cost $1.5–$2.0 million; funding and execution are uncertain.
- The auditor and management identify substantial doubt about the company’s ability to continue as a going concern, citing recurring losses and operating cash burn. Management expects to seek additional debt or equity financing, with no assurance it will be available.
- On March 6, 2024, Health Canada advised that the products did not meet its conditions for marketing as cosmetics; the company voluntarily halted Canadian sales while engaging with the regulator. Canadian distributor sales contributed $158,603, or about 9.3% of FY2023 revenue.
- On March 6, 2024, Nasdaq notified the company of noncompliance with the $1.00 minimum bid-price requirement. Failure to regain compliance could lead to delisting.
- The company depends heavily on its E-Series products and third parties for key inputs and formulation; three suppliers represented 73% of inventory procurement and production costs in FY2023. Clinical evidence is limited, and the company cites regulatory, product-claim, competition, customer-concentration, and financing risks.
- Management identified a material weakness in internal control over financial reporting involving insufficiently designed and operating accounting controls, including standardized reconciliations. The filing also contains inconsistent statements about whether disclosure controls were effective; investors should review the full Item 9A disclosure.
- The DermapenWorld agreement was not renewed and ended January 16, 2024. No active legal proceedings were reported. The company says it has no material off-balance-sheet arrangements.
Investor verification priorities
- Confirm the issuer: this document identifies Elevai Labs Inc. (Nasdaq: ELAB), not PMGC Holdings Inc.
- Review the going-concern assessment, financing needs, cash runway, and subsequent financing activity.
- Check Health Canada’s final product classification and the status and commercial impact of Canadian sales restrictions.
- Verify Nasdaq bid-price compliance and any consequences for listing or access to capital.
- Assess progress remediating the material weakness and clarify the conflicting disclosure-controls statements.
- Validate revenue growth, customer and supplier concentration, product claims, clinical substantiation, and the planned capacity-expansion funding.